UBS Group
ABUS icon

UBS Group’s Arbutus Biopharma ABUS Stock Holding History

UBS Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Buy
364,471
+217,179
+147% +$950K ﹤0.01% 5147
2025
Q4 		$708K Sell
147,292
-627,302
-81% -$2.82M ﹤0.01% 5852
2025
Q3 		$3.52M Buy
774,594
+584,386
+307% +$2.15M ﹤0.01% 4406
2025
Q2 		$588K Sell
190,208
-2,084
-1% -$6.92K ﹤0.01% 5874
2025
Q1 		$671K Buy
192,292
+91,287
+90% +$304K ﹤0.01% 5612
2024
Q4 		$330K Sell
101,005
-67,369
-40% -$248K ﹤0.01% 6133
2024
Q3 		$648K Buy
168,374
+112,709
+202% +$432K ﹤0.01% 5023
2024
Q2 		$172K Sell
55,665
-79,158
-59% -$237K ﹤0.01% 5767
2024
Q1 		$348K Sell
134,823
-5,148
-4% -$13.3K ﹤0.01% 5463
2023
Q4 		$350K Buy
139,971
+77,353
+124% +$151K ﹤0.01% 5383
2023
Q3 		$127K Sell
62,618
-5,549
-8% -$11.6K ﹤0.01% 5675
2023
Q2 		$157K Buy
68,167
+31,502
+86% +$82K ﹤0.01% 5651
2023
Q1 		$111K Buy
36,665
+13,376
+57% +$37.7K ﹤0.01% 5835
2022
Q4 		$54.3K Buy
+23,289
New +$55.7K ﹤0.01% 6691
2022
Q2 		– Sell
-1,298
Closed -$4K – 10231
2022
Q1 		$4K Sell
1,298
-32,810
-96% -$100K ﹤0.01% 9264
2021
Q4 		$132K Buy
+34,108
New +$132K ﹤0.01% 6039
2021
Q3 		– Sell
-62,310
Closed -$189K – 9457
2021
Q2 		$189K Sell
62,310
-10,805
-15% -$33.5K ﹤0.01% 5393
2021
Q1 		$244K Buy
73,115
+55,189
+308% +$213K ﹤0.01% 5338
2020
Q4 		$64K Buy
17,926
+10,913
+156% +$38.2K ﹤0.01% 5968
2020
Q3 		$22K Sell
7,013
-317,279
-98% -$965K ﹤0.01% 6227
2020
Q2 		$590K Sell
324,292
-45,856
-12% -$75K ﹤0.01% 3996
2020
Q1 		$374K Buy
370,148
+126,930
+52% +$343K ﹤0.01% 4216
2019
Q4 		$676K Buy
243,218
+57,094
+31% +$92.4K ﹤0.01% 4566
2019
Q3 		$284K Buy
186,124
+19,715
+12% +$34K ﹤0.01% 4981
2019
Q2 		$346K Buy
166,409
+160,650
+2,790% +$411K ﹤0.01% 4549
2019
Q1 		$21K Buy
5,759
+1,154
+25% +$4.43K ﹤0.01% 6261
2018
Q4 		$18K Buy
4,605
+3,218
+232% +$15.8K ﹤0.01% 6863
2018
Q3 		$13K Sell
1,387
-36,375
-96% -$361K ﹤0.01% 7026
2018
Q2 		$276K Sell
37,762
-4,203
-10% -$25K ﹤0.01% 4736
2018
Q1 		$210K Sell
41,965
-2,396
-5% -$12.7K ﹤0.01% 4753
2017
Q4 		$224K Sell
44,361
-8,205
-16% -$48.1K ﹤0.01% 4832
2017
Q3 		$326K Buy
52,566
+52,451
+45,610% +$224K ﹤0.01% 4523
2017
Q2 		$0 Sell
115
-1,739
-94% -$5.98K ﹤0.01% 7613
2017
Q1 		$6K Buy
+1,854
New +$5.14K ﹤0.01% 6876
2016
Q4 		– Sell
-5,500
Closed -$19K – 7739
2016
Q3 		$19K Sell
5,500
-578
-10% -$2.26K ﹤0.01% 6318
2016
Q2 		$21K Buy
6,078
+345
+6% +$1.46K ﹤0.01% 6256
2016
Q1 		$24K Sell
5,733
-2,326
-29% -$8.31K ﹤0.01% 6058
2015
Q4 		$35K Buy
8,059
+547
+7% +$3K ﹤0.01% 6173
2015
Q3 		$46K Sell
7,512
-6,949
-48% -$61.6K ﹤0.01% 5914
2015
Q2 		$172K Buy
14,461
+13,592
+1,564% +$207K ﹤0.01% 4998
2015
Q1 		$15K Sell
869
-995
-53% -$20.4K ﹤0.01% 7268
2014
Q4 		$28K Buy
+1,864
New +$32.2K ﹤0.01% 7178

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

UBS Group's ABUS Position: Q1 2026 in Review

UBS Group increased its Arbutus Biopharma (ABUS) stake by 147% in Q1 2026, buying an estimated $950K and bringing the position to 364,471 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5147.

UBS Group first reported a position in ABUS in Q4 2014 and has held it in 42 quarters since. The position peaked at $3.52M in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • UBS Group held 364,471 shares of Arbutus Biopharma worth $1.64M as of Q1 2026.
  • UBS Group bought 217,179 Arbutus Biopharma shares in Q1 2026, an estimated $950K.
  • Arbutus Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5147 holding.
  • UBS Group first reported a position in Arbutus Biopharma in Q4 2014 and has held it in 42 quarters since.
  • UBS Group's Arbutus Biopharma position peaked at $3.52M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.